Bloom Burton Weighs in on Zymeworks FY2025 Earnings

Key Points

• Zymeworks Inc. is projected to earn ($1.13) per share in FY2025, which is an improvement from the current consensus estimate of ($1.39) per share for the full year.
• The company reported a significant revenue increase of 153.2% year-over-year for the last quarter, bringing in $48.73 million, far surpassing analyst expectations.
• Zymeworks has a current average price target of $21.43, with most analysts rating the stock as a "Moderate Buy."

Zymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Bloom Burton issued their FY2025 earnings per share estimates for Zymeworks in a research note issued on Wednesday, September 3rd. Bloom Burton analyst D. Martin anticipates that the company will post earnings per share of ($1.13) for the year. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Bloom Burton also issued estimates for Zymeworks' FY2026 earnings at ($1.93) EPS and FY2027 earnings at ($2.11) EPS.

Zymeworks (NYSE:ZYME - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.55. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The company had revenue of $48.73 million for the quarter, compared to analyst estimates of $17.18 million. During the same period last year, the company earned ($0.49) earnings per share. The business's revenue was up 153.2% compared to the same quarter last year.

A number of other research firms have also issued reports on ZYME. TD Securities started coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating on the stock. TD Cowen started coverage on Zymeworks in a research report on Tuesday, May 20th. They set a "buy" rating on the stock. HC Wainwright reissued a "neutral" rating and set a $13.00 target price on shares of Zymeworks in a research report on Thursday, July 3rd. Finally, Citigroup lifted their target price on Zymeworks from $19.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.43.

Zymeworks Stock Performance

Shares of Zymeworks stock traded up $0.16 during trading on Friday, reaching $15.39. The company's stock had a trading volume of 155,289 shares, compared to its average volume of 525,529. The business's fifty day moving average price is $13.74 and its 200-day moving average price is $12.66. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -10.25 and a beta of 1.27. Zymeworks has a one year low of $9.03 and a one year high of $17.70.

Institutional Trading of Zymeworks

Several hedge funds have recently modified their holdings of the company. Janney Montgomery Scott LLC lifted its position in Zymeworks by 12.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company's stock worth $138,000 after buying an additional 1,300 shares in the last quarter. Nuveen LLC bought a new stake in shares of Zymeworks during the first quarter valued at approximately $2,368,000. Nuveen Asset Management LLC grew its stake in shares of Zymeworks by 0.4% during the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock valued at $3,031,000 after purchasing an additional 886 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Zymeworks by 170.3% in the 1st quarter. Vestal Point Capital LP now owns 500,000 shares of the company's stock valued at $5,955,000 after buying an additional 315,000 shares during the period. Finally, EcoR1 Capital LLC increased its stake in shares of Zymeworks by 14.8% in the 1st quarter. EcoR1 Capital LLC now owns 17,259,548 shares of the company's stock valued at $205,561,000 after buying an additional 2,231,469 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.